Preferred Stock

The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share. There were no shares of preferred stock outstanding at March 31, 2018 and December 31, 2017.

Common Stock

As of March 31, 2018 and December 31, 2017, the Company was authorized to issue 75,000,000 shares of its common stock, and 36,726,084 and 36,725,499 shares of common stock, respectively, were outstanding. After giving effect to shares reserved for the issuance of warrants and stock options, 33,617,806 shares of common stock were available for issuance as of March 31, 2018. As of March 31, 2018 and December 31, 2017, 8,591,160 shares of the Company’s non-voting common stock were authorized, issued and outstanding.

Equity Incentive Plan

The fair value of stock options granted under the Company’s 2007 Employee Stock Option Plan (the “2007 Plan”) and the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended and restated (the “2014 Plan”), was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2018 and 2017:

The weighted average remaining contractual life of stock options outstanding and expected to vest at March 31, 2018 is 8.1 years. The weighted average remaining contractual life of stock options exercisable at March 31, 2018 is 5.8 years.

A summary of the Company’s option activity under the 2007 Plan and 2014 Plan and related information is as follows:

During the three months ended March 31, 2018, an aggregate of 1,959 option shares were exercised in cashless exercise transactions resulting in the issuance of an aggregate of 585 shares of common stock. Stock-based compensation expense for the three months ended March 31, 2018 and 2017 is as follows:

As of March 31, 2018, the Company had $5.3 million of unrecognized compensation expense related to options granted under the Company’s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.0 years.